Home Clinical trials For patients Ovary BGOG-ov97/FRAmework01

BGOG-ov97/FRAmework01

A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer (JZXB)

Open
Trial drug
LY4170156
Grade
High grade
Prior lines
1, 2, 3
Histology
Serous, Endometrioid Carcinocarcoma
Platin
Platinum resistant
Secondary platinum refractory
Platinum sensitive
Phase
III

Treatment

Part A : Maladie résistante au platine : 
  • Sofetabart Mipitecan (LY4170156) 
  • Au choix de l'investigateur : paclitaxel, PLD, gemcitabine ou topotécan
     
Part B : Maladie sensible au platine : 
  • Sofetabart Mipitecan (LY4170156) + bevacizumab
  • Au choix de l'investigateur : carboplatine/paclitaxel, carboplatine/gemcitabine ou carboplatine/PLD + bevacizumab
     

Treatment duration

The treatment can continue until disease progression, unacceptable toxicity or withdrawal of consent.

Contact

To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.